AS1409

Antisoma Research · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	AS1409
Also known as	huBC1-huIL-12
Sponsor	Antisoma Research
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AS1409 CI brief — competitive landscape report
AS1409 updates RSS · CI watch RSS
Antisoma Research portfolio CI